SLU-PP-332 Research: ERRα Pan-Agonism and Exercise Mimetic Biology in Preclinical Models
Published by the Elite Biologix Research Team — Compiled by clinical pharmacists with 27+ years of sterile compounding experience. Independent research compilation for scientific and educational reference only.
Key Takeaways
- SLU-PP-332 is a synthetic benzohydrazide-class pan-ERR agonist targeting estrogen-related receptors α, β, and γ — nuclear receptors that govern mitochondrial biogenesis and oxidative metabolism in skeletal muscle and cardiac tissue.
- In normal-weight mouse models, SLU-PP-332 (50 mg/kg IP) increased treadmill endurance time to exhaustion by 70% and total running distance by 45% vs. vehicle controls (Billon et al., ACS Chemical Biology, 2023).
- Obese mouse models treated for one month gained 10 times less fat than untreated controls, with no change in food intake or locomotor activity (Billon et al., J Pharmacol Exp Ther, 2024).
- The published literature on SLU-PP-332 is intentionally thin — approximately 6-8 primary research papers as of mid-2026. This is an emerging compound with active but early-stage preclinical science.
- SLU-PP-332 is sold exclusively for laboratory and research purposes. It is not approved for human use by the FDA or any regulatory authority.
Among the more scientifically compelling compounds to emerge from academic research programs in recent years, SLU-PP-332 represents a new class of small-molecule probes targeting the estrogen-related receptor (ERR) family. Developed by Thomas P. Burris and colleagues — first at Saint Louis University and subsequently at Washington University in St. Louis and the University of Florida — SLU-PP-332 has generated notable preclinical findings across exercise physiology, cardiac biology, and aging research.
What makes SLU-PP-332 particularly interesting to researchers is its mechanism. Rather than delivering energy substrates or blocking catabolic pathways, this compound appears to directly activate the transcriptional programs that exercise itself induces — essentially instructing skeletal muscle cells to express the gene signature of an endurance-trained state. That is a mechanistically distinct approach from anything previously validated in preclinical models.
This review summarizes the available published literature on SLU-PP-332 as of mid-2026. Researchers should note: the evidence base here is intentionally narrow. We are not summarizing 100 studies. We are summarizing roughly 6-8 primary papers from a research program that is still actively unfolding. That context matters when interpreting these findings.
[INTERNAL-LINK: mitochondrial biogenesis research → MOTS-c preclinical research article]What Is SLU-PP-332? Receptor Targets and Mechanism of Action
SLU-PP-332 is classified as a pan-ERR agonist, binding all three members of the estrogen-related receptor subfamily: ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3). A 2026 pharmacological characterization study reported ERRα EC50 = 0.22 μM and ERRγ EC50 = 0.59 μM for SLU-PP-332, placing it in a moderate-potency range for this receptor class (Okda et al., Int J Biol Macromol, 2026, PMID: 41850449). A next-generation analog, BE5040, achieved ERRα EC50 = 0.002 μM — a 110-fold potency improvement — suggesting this receptor class remains a highly active area of medicinal chemistry.
The ERR family members are constitutively active nuclear receptors. Unlike classical estrogen receptors, they do not require endogenous ligand binding to function. They regulate transcription of genes involved in mitochondrial biogenesis, fatty acid β-oxidation, oxidative phosphorylation, and the TCA cycle. ERRα in particular is considered a master regulator of oxidative metabolism in high-energy-demand tissues including cardiac and skeletal muscle.
SLU-PP-332's proposed mechanism follows this pathway: the compound binds the ERR ligand-binding domain, stabilizes the active receptor conformation, recruits the coactivator PGC-1α, and drives transcriptional activation across a broad set of metabolic target genes. Those targets include TFAM and NRF1 (mitochondrial biogenesis), all five electron transport chain complex subunits (OXPHOS), fatty acid β-oxidation enzymes, TCA cycle enzymes, and exercise-response genes including Ddit4 and Slc25a25. The net effect, at least in rodent models, appears to recapitulate the transcriptional signature that aerobic endurance training produces in skeletal muscle and cardiac tissue.
Research context: The specificity of SLU-PP-332's pharmacology deserves attention. The 2023 Billon et al. study included an ERRα knockout arm — mice genetically engineered to lack the receptor. In those animals, SLU-PP-332 produced no endurance enhancement whatsoever (PMID: 36988910). That negative control is important: it confirms the compound's effect is receptor-mediated, not a non-specific metabolic artifact. In pharmacological research, a clean negative control in a knockout model is one of the stronger mechanistic validations available in preclinical work. The ERRα knockout finding elevates SLU-PP-332 above many exercise mimetic candidates that lack this level of mechanistic confirmation.
How Does SLU-PP-332 Compare to Other ERR Research Compounds?
The ERR receptor family has attracted research interest for more than a decade, but potent, selective small-molecule agonists have been historically difficult to develop. SLU-PP-332 and its analogs represent some of the most potent ERR pan-agonists characterized to date. The table below shows the ERRα EC50 values across the SLU-PP-332 series as characterized in the 2026 pharmacological study (Okda et al., Int J Biol Macromol, 2026).
| Compound | ERRα EC50 | Relative Potency vs. SLU-PP-332 | Status |
|---|---|---|---|
| SLU-PP-332 | 0.22 μM | Reference | Primary research compound; multiple published in vivo studies |
| BE5112 | 0.098 μM | ~2.2× more potent | Next-gen analog; limited published in vivo data |
| BE5040 | 0.002 μM | ~110× more potent | Next-gen analog; emerging compound, minimal in vivo data |
| SLU-PP-915 | Not yet published | Oral analog | Orally active; 2026 publication confirms aerobic exercise capacity enhancement |
| Source: Okda et al., Int J Biol Macromol, 2026 (PMID: 41850449); Billon et al., J Pharmacol Exp Ther, 2026 (PMID: 41421047). EC50 values are in vitro binding assay data — in vivo potency relationships may differ. | |||
Researchers sometimes ask how SLU-PP-332 compares to GW501516 (Cardarine), a PPARδ agonist that attracted significant exercise mimetic research interest before being abandoned. The comparison is mechanistically imprecise — GW501516 acts on a different receptor (PPARδ), while SLU-PP-332 targets ERRα/β/γ. More importantly, GW501516 was discontinued after preclinical carcinogenicity signals emerged in long-term rodent studies. SLU-PP-332 has no published carcinogenicity data in either direction — that is a research gap, not a safety endorsement. Researchers investigating either compound should treat long-term safety as an open and unresolved question.
Elite Biologix research compounds are supplied at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis. Browse our research compound catalog for current availability.
Skeletal Muscle Endurance Research: The 2023 ACS Chemical Biology Findings
The most-cited SLU-PP-332 publication to date is a 2023 study by Billon and colleagues in ACS Chemical Biology. The researchers administered SLU-PP-332 at 50 mg/kg IP to normal-weight mice and measured treadmill endurance. Animals treated with SLU-PP-332 ran 70% longer to exhaustion and covered 45% greater total distance compared to vehicle-treated controls (Billon et al., ACS Chem Biol, 2023, PMID: 36988910). As noted above, ERRα knockout mice showed no enhancement — establishing receptor specificity.
The investigators also characterized the transcriptional changes in skeletal muscle. SLU-PP-332 treatment activated exercise-response gene signatures including Ddit4 and Slc25a25, upregulated fatty acid β-oxidation enzyme expression, and increased markers of mitochondrial biogenesis. The pattern closely mirrored the transcriptional response observed in endurance-trained muscle — which is precisely the mechanistic claim the ERRα agonism hypothesis predicts.
An important caveat: these are single acute-exposure treadmill experiments in mice. The study does not address chronic dosing protocols, dose-response relationships across multiple concentrations, or what happens to endurance capacity after washout. Those are standard follow-up questions in exercise mimetic research that the current literature has not yet resolved for SLU-PP-332 specifically.
[INTERNAL-LINK: oxidative phosphorylation and NAD+ preclinical research → NAD+ article]Is SLU-PP-332 Relevant to Obesity and Metabolic Research?
A 2024 study in Journal of Pharmacology and Experimental Therapeutics extended the SLU-PP-332 research into obesity models. Obese mice treated twice daily for one month with SLU-PP-332 gained 10 times less fat than untreated controls and lost approximately 12% of body weight — without any measured change in food intake or locomotor activity (Billon et al., J Pharmacol Exp Ther, 2024, PMID: 37739806). The absence of hypophagia or hyperactivity as confounders is notable: it suggests the compound's metabolic effects in this model were driven by altered energy expenditure at the cellular level rather than behavioral changes.
The mechanistic explanation here is consistent with the ERRα pathway. Upregulation of fatty acid β-oxidation gene programs in skeletal muscle and adipose tissue would be expected to increase caloric expenditure independent of locomotion. Whether this translates to other species or survives longer exposure windows remains an open research question.
What the obesity data does not establish: mechanism of fat distribution changes, effects on lean mass, cardiovascular safety at chronic doses, or what happens after treatment is stopped. Researchers should interpret these findings as hypothesis-generating rather than conclusive.
Cardiac Biology: Pressure Overload and Heart Failure Models
A 2024 study in Circulation by Xu and colleagues examined SLU-PP-332 alongside a structural analog (SLU-PP-915) in a pressure overload heart failure mouse model. Treated animals showed improved ejection fraction, reduced cardiac fibrosis, and increased survival compared to untreated controls (Xu et al., Circulation, 2024, PMID: 37961903). The investigators reported activation of fatty acid metabolism and OXPHOS gene programs in cardiac tissue — consistent with the compound's proposed mechanism in skeletal muscle.
This is arguably the most clinically interesting publication in the SLU-PP-332 literature, given the unmet research need in cardiac metabolic biology. Failing hearts are known to downregulate fatty acid oxidation in favor of glucose metabolism — an adaptive shift that becomes maladaptive over time. ERRα agonism, by restoring oxidative gene programs, represents a mechanistically rational approach to that problem in preclinical models.
The caveat is equally important: pressure overload mouse models are imperfect analogs for human heart failure, and the compound's effects on long-term cardiac remodeling, arrhythmia risk, or off-target cardiovascular endpoints have not been published. The Circulation findings warrant follow-up research, but they do not constitute safety or efficacy data for any clinical application.
Aging and Mitochondrial Biology: What the Geriatric Mouse Models Show
Among the most compelling SLU-PP-332 publications is a 2023 study by Wang and colleagues in American Journal of Pathology using 21-month-old mice — roughly equivalent to elderly humans in rodent lifespan terms. Animals received 25 mg/kg/day for 8 weeks. The investigators reported that SLU-PP-332 restored skeletal muscle PGC-1α and PGC-1β expression to levels comparable to young mice, upregulated all five electron transport chain complex subunits, and restored Mitofusin-2 — a protein critical to mitochondrial fusion dynamics (Wang et al., Am J Pathol, 2023, PMID: 37717940).
Beyond mitochondrial structure, the study documented inflammatory changes: SLU-PP-332 treatment decreased cGAS, STING, IL-1β, TNF-α, and STAT3 in aged muscle — markers collectively associated with mitochondrial stress-driven inflammation, sometimes called "mtDNA-DAMP signaling." The cGAS-STING pathway in particular has attracted considerable attention in aging biology as a driver of sterile inflammation.
A 2025 study in Frontiers in Physiology added a human cell data point. In inactive myoblasts derived from elderly women (mean age approximately 78 years), SLU-PP-332 reduced intracellular reactive oxygen species by 37.7%, increased reduced glutathione by 117.4%, and reduced β-galactosidase — a senescence marker — by 26.1% (Frontiers in Physiology, 2025, DOI: 10.3389/fphys.2025.1616693). This is one of the very few SLU-PP-332 studies to use human-derived cells, making it a meaningful addition despite its in vitro design.
[IMAGE: Diagram of ERRα-PGC-1α transcriptional complex activating mitochondrial biogenesis gene programs in skeletal muscle - search terms: mitochondria biogenesis diagram scientific illustration]What Does the Preclinical Data Look Like Together? A Summary
The published SLU-PP-332 findings, taken together, describe a compound that activates ERRα-dependent transcriptional programs in multiple metabolically active tissues. The table below summarizes the primary quantitative outcomes across the published rodent and cell model studies as of mid-2026.
| Model / Study | Key Outcome | Magnitude | Source |
|---|---|---|---|
| Normal-weight mice — treadmill | Increased time to exhaustion | +70% | Billon et al., ACS Chem Biol, 2023 |
| Normal-weight mice — treadmill | Increased total running distance | +45% | Billon et al., ACS Chem Biol, 2023 |
| Obese mice — 1-month treatment | Reduced fat mass gain vs. controls | 10× less fat gained | Billon et al., J Pharmacol Exp Ther, 2024 |
| Elderly human myoblasts (in vitro) | Reduced intracellular ROS | -37.7% | Frontiers in Physiology, 2025 |
| Elderly human myoblasts (in vitro) | Increased reduced glutathione | +117.4% | Frontiers in Physiology, 2025 |
| Elderly human myoblasts (in vitro) | Reduced senescence marker (β-gal) | -26.1% | Frontiers in Physiology, 2025 |
| Aged mice (21-month) — 8 weeks | Restored PGC-1α/β to young-mouse levels; decreased cGAS, STING, IL-1β, TNF-α | Normalized to young controls | Wang et al., Am J Pathol, 2023 |
| All data from rodent in vivo or in vitro human cell studies. No human clinical trial data exists for SLU-PP-332 as of mid-2026. Effect magnitudes are not predictive of human outcomes. | |||
What this body of data does not contain is equally important to note. There are no published pharmacokinetic studies in species other than rodents. There is no published toxicology profile beyond acute dosing windows. There are no published data on receptor selectivity effects across the full nuclear receptor superfamily. And there are no human clinical trials at any stage of development. For a research compound in 2026, that is where SLU-PP-332 sits: compelling preclinical proof of concept, with a substantial gap before any translational conclusions could be drawn.
Frequently Asked Questions About SLU-PP-332 Research
What receptor family does SLU-PP-332 target, and why does that matter for metabolic research?
SLU-PP-332 targets estrogen-related receptors α, β, and γ — nuclear transcription factors that control gene expression for mitochondrial biogenesis and oxidative metabolism. ERRα in particular regulates fatty acid oxidation and OXPHOS in skeletal muscle and cardiac tissue. Because these receptors orchestrate the metabolic response to exercise training, ERRα agonism is considered a mechanistically rational approach to studying exercise-mimetic biology in preclinical models (Billon et al., 2023, PMID: 36988910).
How many published studies exist on SLU-PP-332, and is that enough to draw conclusions?
As of mid-2026, approximately 6-8 primary research papers have been published on SLU-PP-332 and its closest analogs. That is a small evidence base. The consistency of findings across independent research groups is encouraging, but the literature lacks long-term toxicology, pharmacokinetic profiling across species, or dose-range studies in any model. Researchers should treat current findings as hypothesis-generating, not confirmatory. The ERRα knockout negative control in the 2023 endurance study is one of the stronger individual data points (PMID: 36988910).
How does SLU-PP-332 differ mechanistically from GW501516 (Cardarine)?
GW501516 acts on PPARδ — a different nuclear receptor with different downstream targets and tissue distribution. SLU-PP-332 targets ERRα/β/γ. The two compounds are not mechanistically comparable. GW501516 was withdrawn from development following preclinical carcinogenicity findings in rodents. SLU-PP-332 has no published carcinogenicity data, which means neither reassurance nor concern can be drawn from GW501516's history. Both are research-only compounds with significant unresolved safety questions.
What was the significance of the ERRα knockout mouse experiment?
In the 2023 Billon et al. study, ERRα knockout mice received the same SLU-PP-332 dose as wild-type animals. They showed no endurance improvement at all (PMID: 36988910). This is pharmacologically significant because it rules out non-receptor-mediated mechanisms as explanations for the endurance data. A clean null result in a knockout model is among the most rigorous mechanistic validations available in preclinical pharmacology, and it meaningfully strengthens the ERRα-dependence interpretation of SLU-PP-332's observed effects.
Is SLU-PP-332 available as a research compound, and what purity standards apply?
SLU-PP-332 is a research-use compound supplied for qualified laboratory applications only. Researchers sourcing SLU-PP-332 should require third-party analytical verification with a published Certificate of Analysis per lot, covering identity, purity (≥98%) and quantitative assay. These two tests confirm both chemical identity and absence of process-related impurities. Certificate of Analysis documentation from an independent laboratory is the minimum standard for any research-grade compound. Elite Biologix research compounds are supplied at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis. Browse our research compound catalog for current availability.
Conclusion: ERRα Agonism as a Framework for Exercise Mimetic Research
SLU-PP-332 occupies an unusual position in the preclinical research landscape. Its mechanism is unusually well-defined for a compound at this stage of development. The ERRα knockout validation, the transcriptional profiling data in skeletal muscle, the cardiac model findings, and the human-derived myoblast work collectively describe a compound that genuinely activates exercise-related gene programs — not through a downstream metabolic effect, but at the transcriptional level where exercise adaptation begins.
At the same time, the literature is genuinely thin. Six to eight primary papers across two to three years of active research is not a deep evidence base. The absence of published toxicology, long-term dosing data, and human pharmacokinetics means that the current findings, however mechanistically compelling, remain early-stage preclinical data. Researchers interested in ERRα biology, mitochondrial biogenesis, or exercise mimetic pharmacology will find SLU-PP-332 a scientifically productive probe compound. Those looking for validated safety and efficacy data will find the literature appropriately described as emerging.
The development of next-generation analogs — particularly the 110-fold potency improvement seen with BE5040 and the oral bioavailability of SLU-PP-915 — suggests the Burris laboratory and collaborators view this receptor class as a durable research target. That ongoing medicinal chemistry activity is itself a signal that the preclinical findings have generated sufficient confidence to pursue structural optimization.
SLU-PP-332 is sold exclusively for laboratory and research purposes. It is not approved for human use by the FDA or any regulatory authority.
References
- Billon C, et al. "SLU-PP-332 Is a Potent and Selective Estrogen-Related Receptor Pan-Agonist That Activates ERRα in an Exercise-Like Manner." ACS Chemical Biology. 2023 Apr;18(4):809-818. PMID: 36988910
- Billon C, et al. "Pan-ERR Agonist SLU-PP-332 Prevents Obesity and Metabolic Dysfunction." Journal of Pharmacology and Experimental Therapeutics. 2024 Jan;388(1):248-258. PMID: 37739806
- Xu Y, et al. "ERR Agonism Improves Cardiac Function and Survival in a Mouse Model of Pressure Overload-Induced Heart Failure." Circulation. 2024 Jan;149(2):149-163. PMID: 37961903
- Wang Y, et al. "SLU-PP-332 Reverses Age-Associated Mitochondrial Dysfunction and Inflammation in Skeletal Muscle." American Journal of Pathology. 2023 Dec;193(12):1934-1949. PMID: 37717940
- Billon C, et al. "Orally Active ERR Pan-Agonist SLU-PP-915 Enhances Aerobic Exercise Capacity." Journal of Pharmacology and Experimental Therapeutics. 2026 Jan. PMID: 41421047
- Okda TM, et al. "Pharmacological Characterization of SLU-PP-332 and Next-Generation ERR Agonist Analogs." International Journal of Biological Macromolecules. 2026 Mar. PMID: 41850449
- Frontiers in Physiology Research Team. "SLU-PP-332 Reduces Oxidative Stress and Senescence Markers in Human Myoblasts from Elderly Women." Frontiers in Physiology. 2025 Jul. DOI: 10.3389/fphys.2025.1616693
SLU-PP-332 is sold exclusively for laboratory and research purposes. It is not approved for human use by the FDA or any regulatory authority. All information presented in this article is derived from peer-reviewed preclinical research and is intended for scientific and educational reference only. Elite Biologix does not make any therapeutic or health claims regarding this or any research compound. Published by the Elite Biologix Research Team — reviewed by PCCA-certified specialists in peptide formulation and functional medicine.
